Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

Acute kidney injury

Alistair Connell and Chris Laing
Download PDF
DOI: https://doi.org/10.7861/clinmedicine.15-6-581
Clin Med December 2015
Alistair Connell
AInstitute of Human Health and Performance, UCL, London, UK
Roles: clinical fellow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: alistair.connell@ucl.ac.uk
Chris Laing
BDepartment of Nephrology, Royal Free London NHS Foundation Trust, London, UK
Roles: consultant nephrologist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

ABSTRACT

Acute kidney injury (AKI) – an abrupt deterioration in renal function – causes a rise in serum creatinine (SCr) or fall in urine output. It is common, occurring in up to 20% of hospital admissions. Importantly, even small rises in SCr are associated with increased risk of death and longer hospital stays. A 2009 National Confidential Enquiry into Patient Outcome and Death report found that a proportion of AKI in secondary care was avoidable. In addition, management of established AKI was ‘good’ less than half the time. In practice, AKI represents a heterogeneous group of conditions, encompassing impairments in both kidney structure and function. Delivering disease-specific treatment early in the course of AKI may improve outcomes. The provision of best-practice care for all will rely on a better understanding of risk, and frameworks of care that can be applied across a diverse patient group.

KEYWORDS
  • Nephrology
  • acute kidney injury
Key points
  • Acute kidney injury (AKI) reflects a heterogeneous group of structural and functional diseases of the kidney.

  • It is common, and associated with significant morbidity and mortality.

  • A proportion of AKI is predictable, preventable or recognised late.

  • Risk relates to both acute insults and comorbid disease.

  • Care bundles can ensure timely diagnosis, appropriate supportive care, targeted therapy and referral.

Introduction – definitions and importance

Acute kidney injury (AKI) – an abrupt deterioration in renal function- causes a rise in serum creatinine (SCr) and/or fall in urine output. The magnitude of these changes is used to stratify the severity of AKI, as defined in an internationally agreed system of classification designed for clinical practice and research (KDIGO).1 Using this classification, AKI is common, occurring in up to 20% of hospital admissions.2 Importantly, even small rises in SCr are independently associated with an increased risk of death.2 Some 40,000 excess deaths are attributed to AKI each year in England alone;3 a mortality burden greater than that attributable to MRSA and venous thromboembolism combined.4 Morbidity is also high in AKI; it is associated with an increased length of stay,3 and the development of chronic kidney disease.5 This is expensive; one recent economic analysis estimated the associated healthcare costs for England alone to be over £1 billion per annum; a yearly cost that exceeds treatment for some major cancers.3

In practice, AKI represents a heterogeneous group of conditions, encompassing impairments in kidney structure and function. Of those diagnosed with AKI in hospital, roughly half will have effective hypovolaemia or sepsis.6 The remaining cases are caused by a mixture of obstructive uropathy, nephrotoxins and a variety of parenchymal renal diseases. The London AKI Network has produced comprehensive guidelines and care pathways, designed to assist clinicians in routine management. Their summary of the main causes of AKI is shown in Box 1.

Understanding risk in AKI

A 2009 National Confidential Enquiry into Patient Outcome and Death (NCEPOD) report found that the care of patients with established AKI was ‘good’ less than half the time.7 The potential for the reduction of patient morbidity, mortality and healthcare costs in AKI are thus clear. Alongside sepsis, the NHS Five year forward view identified improving AKI care as an area that will maximally reduce avoidable mortality.8 Improving outcomes at scale will depend on better understanding of risk, and the consistent delivery of best-practice care.

View this table:
  • View inline
  • View popup
Box 1.

The primary causes of AKI. Reproduced with permission from the London AKI Network.

The 2009 NCEPOD report also highlighted that up to 20% of AKI in secondary care was avoidable. The chance of developing AKI following exposure to an insult depends on a host of individual factors. These relate to both underlying susceptibilities (eg existing chronic kidney disease or diabetes) and exposures in hospital (eg sepsis or major surgery).9 Care should be taken to ensure that these exposures are minimised for patients at risk; this will include ensuring volume status is optimised and the avoidance of nephrotoxins. Monitoring of serum creatinine and urine output is also important for early recognition of AKI; but it should also be borne in mind that rises in SCr will lag behind any drops in in glomerular filtration rate following an insult to the kidneys by several days.

An organised approach to patient management

While the relationship between AKI, critical illness and comorbidities is complex, there is broad recognition that a strategy of early intervention may avoid significant parenchymal injury in patients with multi-system illness.10,11 Early review by a nephrology team may help ameliorate AKI,12 but the numbers of patients developing AKI and the centralisation of services make this impossible for all. As a result, local and regional care protocols exist for monitoring, investigation and supportive care (see Fig 1 for an example of such a pathway).13

Fig 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 1.

An AKI care bundle. Reproduced with permission from the London AKI Network. ACE = angiotensin-converting-enzyme; AKI = acute kidney injury; ARB = angiotensin-receptor blocker; Bili = bilirubin; CK = creatine kinase; CRP = C-reactive protein; HUS = hemolytic-uremic syndrome; LDH = lactate dehydrogenase; NSAIDs = non-steroidal anti-inflammatory drugs; PCR = protein-creatinine ratio; retics = reticulocytes; TTP = thrombotic thrombocytopenic purpura.

Managing complications and tertiary referral

Patients with established AKI must also be monitored for complications; some may need to be cared for in higher acuity areas of care. Care protocols can guide immediate management and ensure patient safety (see Fig 2).

Fig 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 2.

Managing complications in AKI. Reproduced with permission from the London AKI Network. AKI = acute kidney injury; ECG = echocardiogram; ECF = extracellular fluid; GTN = glyceryl trinitrate.

In addition, for any AKI patient with one of the above complications, local critical care services should be contacted for patients with AKI3 (serum creatinine >3X baseline OR >354 μmol/L OR initiation of renal replacement therapy), or those in whom imminent recovery is unlikely. Urgent referral to local urological services is warranted for those with obstruction on ultrasound. In the first instance, referrals to local nephrology services should be reserved for patients with AKI and the following:

  • myeloma

  • suspected autoimmune disease or glomerulonephritis (positive autoimmune screen; blood or protein on urine dip)

  • suspected hemolytic–uremic syndrome and thrombotic (history of diarrhoea or rash)

  • thrombocytopenic purpura

  • suspected poisoning.

Future frameworks for care

Recent local and national initiatives have focused on early recognition and timely intervention, leading to the adoption of real-time automated diagnostic algorithms.14 NHS England have produced one such algorithm, mandating that it be incorporated in some way into all hospital laboratory information management systems. Alerts for patients with AKI are to be displayed in patient management systems and reported centrally.15 However, trials of automated clinical decision support tools have had mixed results. A recent randomised controlled trial testing the efficacy of simple electronic e-alerting for AKI resulted in no significant differences in patient peak creatinine, requirement for dialysis or risk of death.16 As discussed above, patients with AKI form a heterogeneous group, and therapy is not standardised; a new process may be needed to guide the nature and scale of clinical response in the right timeframe. It has already been demonstrated that existing patient data can be used to reduce false positive alerts (eg patients with chronic kidney disease or on renal replacement therapy).17 As computers become more powerful and patient-specific data are coded with greater granularity, the potential for more advanced risk prediction using artificial intelligence is huge.

Current approaches in the diagnosis of AKI are also limited by the regularity with which SCr or urine output are measured. In the future, strategies may focus on fostering early detection and more targeted therapy. Numerous novel biomarkers reflecting function or structural damage to the kidney have been investigated (neutrophil gelatinase-associated lipocalin, kidney injury molecule 1). Although there is hope that they may one day facilitate earlier diagnosis or differentiate separate causal pathways, current approaches lack sensitivity and may be less effective at the level of the individual patient. Crucially, they have yet to consistently show value in clinical decision making above and beyond existing SCr and urine output monitoring. Future efforts may focus on their use alongside existing biochemical and clinical information.18

  • © Royal College of Physicians 2015. All rights reserved.

References

  1. 1.↵
    1. KDIGO
    . KDIGO Clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012;2:1–138.
    OpenUrlCrossRef
  2. 2.↵
    1. Wang HE
    , Muntner P, Chertow GM, et al. Acute kidney injury and mortality in hospitalized patients. Am J Nephrol 2012;35:349–55.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Kerr M
    ; Bedford M; Matthews B, et al. The economic impact of acute kidney injury in England. Nephrol Dial Transplant 2014;29:1362–8.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Fluck R.
    Acute kidney injury: common, harmful, treatable. London: NHS England. Available online at www.england.nhs.uk/wp-content/uploads/2014/03/bg-present-keep-kidneys.pdf [Accessed 5 October 2015].
  5. 5.↵
    1. Coca SG
    , Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int 2012;81:442–8.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Chawla LS.
    Disentanglement of the acute kidney injury syndrome. Curr Opin Crit Care 2012;82:516–24.
    OpenUrl
  7. 7.↵
    1. National Confidential Enquiry into Patient Outcome and Death
    . Acute kidney injury: adding insult to injury. London: NCEPOD, 2009. Available online at www.ncepod.org.uk/2009aki.htm [Accessed 5 October 2015].
  8. 8.↵
    1. NHS England
    . The forward view into action: planning for 2015/16. London: NHS England. London: NHS England, 2014. Available online at www.england.nhs.uk/wp-content/uploads/2014/12/forward-view-plning.pdf [Accessed 5 October 2015].
  9. 9.↵
    1. Kellum JA
    , Lameire N; KDIGO Guideline Work Group AKI. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care 2013;17:204.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Ronco C
    , Kellum JA, Bellomo R, et al. Potential Interventions in Sepsis-Related Acute Kidney Injury. Clin J Am Soc Nephrol 2008;3:531–44.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Schrier RW.
    Fluid administration in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol 2010;5:733–9.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Balasubramanian G
    , Al-Aly Z, Moiz A, et al. Early nephrologist involvement in hospital-acquired acute kidney injury: a pilot study. Am J Kidney Dis 2011;57:228–34.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. London Acute Kidney Injery Network
    . Guidelines and pathways. London: London AKI Network, 2015. Available online at www.londonaki.net/clinical/guidelines-pathways.html [Accessed 5 October 2015].
  14. 14.↵
    1. Selby NM
    , Crowley L, Fluck RJ, et al. Use of electronic results reporting to diagnose and monitor AKI in hospitalized patients. Clin J Am Soc Nephrol 2012;7:533–40.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. NHS England
    . NHS Patient Safety Alert: NHS/PSA/D/2014/010. London: NHS England, 2014. Available online at www.england.nhs.uk/wp-content/uploads/2014/06/psa-aki.pdf [Accessed 5 October 2015].
  16. 16.↵
    1. Wilson FP
    , Shashaty M, Testani J, et al. Automated, electronic alerts for acute kidney injury: a single-blind, parallel-group, randomised controlled trial. Lancet 2015;385: 1966–74.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Celi LAG
    , Tang RJ, Villarroel MC, et al. A clinical database-driven approach to decision support: predicting mortality among patients with acute kidney injury. J Healthc Eng 2011;2:97–110.
    OpenUrlPubMed
  18. 18.↵
    1. Lameire NH
    , Vanholder RC, Van Biesen WA. How to use biomarkers efficiently in acute kidney injury. Kidney Int 2011;79:1047–50.
    OpenUrlCrossRefPubMed
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Acute kidney injury
Alistair Connell, Chris Laing
Clinical Medicine Dec 2015, 15 (6) 581-584; DOI: 10.7861/clinmedicine.15-6-581

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Acute kidney injury
Alistair Connell, Chris Laing
Clinical Medicine Dec 2015, 15 (6) 581-584; DOI: 10.7861/clinmedicine.15-6-581
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • ABSTRACT
    • Introduction – definitions and importance
    • Understanding risk in AKI
    • An organised approach to patient management
    • Managing complications and tertiary referral
    • Future frameworks for care
    • References
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Scoping review exploring the impact of digital systems on processes and outcomes in the care management of acute kidney injury and progress towards establishing learning healthcare systems
  • A scoping review exploring the impact of digital systems on processes and outcomes in the care management of acute kidney injury and progress towards establishing learning healthcare systems
  • Google Scholar

More in this TOC Section

  • The health impacts of dietary sodium and a low-salt diet
  • Isolated microscopic haematuria of glomerular origin: clinical significance and diagnosis in the 21st century
Show more CME Renal Medicine

Similar Articles

FAQs

  • Difficulty logging in.

There is currently no login required to access the journals. Please go to the home page and simply click on the edition that you wish to read. If you are still unable to access the content you require, please let us know through the 'Contact us' page.

  • Can't find the CME questionnaire.

The read-only self-assessment questionnaire (SAQ) can be found after the CME section in each edition of Clinical Medicine. RCP members and fellows (using their login details for the main RCP website) are able to access the full SAQ with answers and are awarded 2 CPD points upon successful (8/10) completion from:  https://cme.rcplondon.ac.uk

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians